CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Reliance share zooms on joining hands with BP to set up second new deepwater gas field

DSIJ Intelligence 0 1484 Article rating: 3.7

Reliance Industries Limited (RIL) informed today that it has collaborated with BP, one of the world's seven oil & gas ‘supermajors’ and British multinational company to commence production from the Satellite Cluster Gas Field in block KG D6, off the east coast of India.  

Biocon Biologics and its partner Viatris get EC nod for biosimilar Bevacizumab

Apurva Joshi 0 983 Article rating: 5.0

Biocon Limited’s subsidiary Biocon Biologics Ltd has informed the bourses that Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. has received marketing authorisation approval from European Commission (EC), following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. 

Natco Pharma seeks emergency nod for its COVID-19 capsules; rises over 6 per cent

Abhinav Lahoti 0 1201 Article rating: 3.8

The company today announced that it has applied to Central Drugs Standard Control Organisation (CDSCO) of India for the approval of phase 3 clinical trials of ‘Molnupiravir’ capsules, which have shown promising results during the treatment of COVID-19 positive patient. 

In conversation with Mahesh Patil, Chief Investment Officer of Aditya Birla Sun Life AMC Ltd

DSIJ Intelligence 0 1317 Article rating: 3.7

We follow a ‘growth at a reasonable price (GARP) investing style’ since it combines the best of both worlds. We have identified themes that provide secular growth opportunities such as private banks, unorganised to organised, speciality chemicals, manufacturing in India, and technology/digital.

Alembic Pharma gets US regulator nod for Doxepin Hydrochloride capsules

DSIJ Intelligence 0 851 Article rating: 5.0

On Friday, Alembic Pharmaceuticals informed the exchanges that it has received final approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Doxepin Hydrochloride capsules, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg & 100 mg.  

Gland Pharma climbs nearly 2 per cent on getting USFDA nod for generic Foscarnet Sodium injection

DSIJ Intelligence 0 805 Article rating: 5.0

Gland Pharma Limited announced after the market hours on Thursday that it has received approval from United States Food & Drug Administration (USFDA) for generic Foscarnet Sodium injection, 6,000 mg/250 ml (24 mg/ml) single-dose bag for infusion.

Caplin Point rises after its subsidiary gets USFDA nod for generic version of Bloxiverz injection

DSIJ Intelligence 0 863 Article rating: 4.0

On Thursday, Caplin Point Laboratories announced that its subsidiary, Caplin Steriles Limited has been granted final approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate injection.   

Betting On Bigger Homes

Ninad Ramdasi 0 621 Article rating: No rating

Given the change in scenario with work-from-home becoming a feasible option, both the salaried and entrepreneurial class of people are now looking at homes with extended space, says Santhosh Kumar, Vice Chairman, Anarock Property Consultants

Query Board

Ninad Ramdasi 0 539 Article rating: No rating

This section gives decisive investment rationales to our subscribers on the stock queries they have raised to our research team.

Vaishali Pharma climbs nearly 5 per cent on receiving supply orders worth Rs 2.02 crore

DSIJ Intelligence 0 799 Article rating: 4.3

Vaishali Pharma Limited, a pharmaceutical company based in Mumbai, announced this morning that it has bagged an order worth Rs 2.02 crore from Afghanistan.  

As per the deal, the company will engage in the supply of active pharmaceutical ingredients (API), packaging material like capsules, glass vials, rubber stoppers, flip-off seals, and sterile water for injection, etc. It will also provide specific machinery setups such as tablet manufacturing machines.

L&T Construction bags contract to build one of worlds largest oil & gas supply bases in Saudi Arabia

Apurva Joshi 0 931 Article rating: 4.7

The buildings & factories business of Larsen & Toubro Construction has secured a significant contract from Oilfields Supply Company in Saudi, owned by Dubai-based Oilfields Supply Center Ltd to design and build one of the world's largest oil & gas supply bases at King Salman Energy Park, Dammam (Kingdom of Saudi Arabia). 

Reviews

Ninad Ramdasi 0 679 Article rating: No rating

In this edition, we have reviewed Hindustan Unilever Ltd. and J B Chemicals and Pharmaceuticals Ltd. We suggest our reader-investors to HOLD in Hindustan Unilever Ltd. and J B Chemicals and Pharmaceuticals

Kerbside

Ninad Ramdasi 0 730 Article rating: No rating

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation

7 Stocks for Your Portfolio

Ninad Ramdasi 0 1684 Article rating: No rating

FY 2021 has been a phenomenal year for equity as an asset class. The question is whether FY 2022 will build on the gains of FY 2021 or will the markets shed some of the weight? Yogesh Supekar discusses in detail how FY 2021 has panned out while the DSIJ Research Team shares their top seven picks to enlighten investors’ portfolio

Policy Analysis

Ninad Ramdasi 0 607 Article rating: No rating

If we purely look from a cost to benefit prespective, then it makes complete sense to invest in normal health insurance policy rather than corona rakshak or corona kavach policy.

Performance Matters

Ninad Ramdasi 0 697 Article rating: No rating

When the markets went into a slump last year on account of the pandemic, we used our experience of many years to cherry-pick mutual funds that investors would do well to choose for their portfolio.

MF Query Board

Ninad Ramdasi 0 609 Article rating: No rating

Readers are requested to send only one query at a time so that more readers get a chance. Have questions relating to any aspect of personal finance. Ask DSIJ at editorial@DSIJ.in and get your queries resolved.

Do Government Policies Impact Stock Markets?

Ninad Ramdasi 0 509 Article rating: No rating

There are very many variables that impact stock prices. However, the government fiscal policy which is announced in the annual budget every year and the monetary policy announced by the Reserve Bank of India have a special significance not only on overall economic growth and stability but also on the equity prices. Geyatee Deshpande analyses the connection and impact of both these policies on the equity prices

Understanding The ‘Price-To-Earning Parameter

Ninad Ramdasi 0 564 Article rating: No rating

Equity valuations, it is said, is the key to understanding the equity markets. Valuation is also one of the most confusing aspects of the equity market game. Shreya Chaware focuses on a group of stocks where the PE expansion was most visible. She also discusses at length why certain stocks always manage to fetch a premium over the other players in the same industry

Smart Beta

Ninad Ramdasi 0 505 Article rating: No rating

Your cover story titled ‘Smart Beta for Volatile Times’ was quite an interesting read and was new to me. 

LETTER

Ninad Ramdasi 0 527 Article rating: No rating

It would be much appreciated if an article could explain the pricing of different shares.

Caplin Point subsidiary gets USFDA approval for Milrinone Lactate injection

DSIJ Intelligence 0 792 Article rating: 4.5

Caplin Point Laboratories Limited announced on Monday after the market hours that its subsidiary company, Caplin Steriles Limited, has been granted final approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Milrinone Lactate injection. 

Max Ventures subsidiary, MSFL commences first of two metalliser lines

Apurva Joshi 0 1196 Article rating: 4.9

Max Ventures & Industries Limited’s (MaxVIL) subsidiary Max Speciality Films Limited (MSFL), which manufactures specialty packaging films, had announced in December 2020 that it will be installing two additional metalliser lines. MSFL has, however, commenced first of the two metalliser lines. 

Infosys partners with Copenhagen Fintech to support development of fintech solutions

DSIJ Intelligence 0 964 Article rating: 4.0

Infosys, a global leader in next-generation digital services & consulting today announced a collaboration with Fintech innovation cluster, Copenhagen Fintech, to strengthen connections across the innovation ecosystem and support the development of fintech solutions for the global financial services industry.   

RSS
First299300301302304306307308Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR